Tagged
8 notes in this topic
Between May and August 2026, four independent reviews mapped the evidence for BPC-157, thymosin beta-4/TB-500 and GHK-Cu. Their shared verdict is worth reading.
An FDA advisory committee recommended six peptides for the 503A compounding list in July 2026. Here is what a non-binding vote does, and does not, mean.
A 32-rat study compared BPC-157, TB-500 and their combination after Achilles transection. TB-500 led on biomechanics; the combination was not additive.
Three decades of rodent studies, a handful of mechanistic papers, and no published human trial. A plain-language map of the BPC-157 literature.
A purity figure is a chromatographic ratio, not a statement about everything in the vial. What the number measures, what it leaves out and how to read it.
One is a gastric peptide acting through VEGFR2 and nitric oxide; the other is a fragment of an actin-binding protein. A side-by-side reading of the evidence.
Thymosin beta-4 is the cell’s main actin-sequestering protein. TB-500 is a short synthetic piece of it. The difference shapes how to read the literature.
Two or three peptides in one vial is a convenience for the bench and a problem for inference. How combination studies are built so results can be attributed.
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.